Impulse control disorders and dopamine agonists.
Hamblin, Ross Ntali, Georgia Karavitaki, Niki
Hamblin, Ross
Ntali, Georgia
Karavitaki, Niki
Abstract
Impulse control disorders (ICDs) are a potentially detrimental group of behaviours with recognised and increasingly reported associations with dopamine agonist (DA) use. As DAs are an established and commonly prescribed treatment for patients with prolactinoma, further understanding of the relationship between DAs and ICDs in this group of patients is merited. In this narrative review, we discuss the evidence to date exploring the prevalence of ICDs in patients with pituitary tumours, examine reasons for considerable variability in reported findings, and appraise and summarise evidence attempting to establish the association between DAs and ICDs. We also outline the recommended clinical approach to these disorders and highlight ongoing uncertainties within the field that warrant further research.
MIDER Authors
Affiliations
Date
2026-04-21
Type
Article
Collections
Citation
Hamblin R, Ntali G, Karavitaki N. Impulse control disorders and dopamine agonists. Best Pract Res Clin Endocrinol Metab. 2026 Apr 21:102104. doi: 10.1016/j.beem.2026.102104.